Rechallenging with clozapine following neutropenia: Treatment options for refractory schizophrenia

American Journal of Psychiatry

Volumn 165, Issue 7, 2008, Pages 813-818

  Ghaznavi, Sharmin ^a   Nakic, Marina ^a   Rao, Paul ^a   Hu, Jian ^a   Brewer, Judson A ^a   Hannestad, Jonas ^a   Bhagwagar, Zubin ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DONEPEZIL; LITHIUM CARBONATE; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ADULT; AFRICAN AMERICAN; AGRANULOCYTOSIS; ANAMNESIS; CASE REPORT; CONFERENCE PAPER; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; MALE; MEDICAL DECISION MAKING; NEUTROPENIA; NEUTROPHIL COUNT; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; RECURRENCE; RISPERIDONE; SCHIZOPHRENIA, PARANOID; SEVERITY OF ILLNESS INDEX;

EID: 46749093738     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.2008.07111823     Document Type: Conference Paper

References (48)

1. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553-564
2. Miller DD: Review and management of clozapine side effects. J Clin Psychiatry 2000; 61(suppl 8):14-17
3. Whiskey E, Taylor D: Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs 2007; 21:25-35
4. Safferman AZ, Lieberman JA, Alvir JM, Howard A: Rechallenge in clozapine-induced agranulocytosis. Lancet 1992; 339:1296-1297
5. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D: Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169:483-488
6. Senechal A, Landry P, Deschamps R, Lessard M: Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs. Encephale 2002; 28(6 part 1):567-569
7. Small JG, Weber MC, Klapper MH, Kellams JJ: Rechallenge of late-onset neutropenia with clozapine. J Clin Psychopharmacology 2005; 25:185-186
8. Dunk LR, Annan LJ, Andrews CD: Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006; 188:255-263
9. Barrons E, Johnson E, Nynkowski P: Restarting clozapine: a case report. Psychiatr Serv 1996; 47:92
10. Haddy TB, Rana SR, Castro O: Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 1999; 133:15-22
11. Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR: Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull 2007; 33:1221-1224
12. Rajagopal S: Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J 2005; 81:545-546
13. Alphs LD, Anand R: Clozapine: the commitment to patient safety. J Clin Psychiatry 1999; 60(suppl 12):39-42
14. Kay SR, Feizbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
15. Patel NC, Dorson PG, Bettinger TL: Sudden late onset of clozapine-induced agranulocytosis. Ann Pharmacother 2002; 36:1012-1015
16. Kutscher EC, Robbins GP, Kennedy WK, Zebb K, Stanley M, Carnahan RM: Clozapine-induced leukopenia successfully treated with lithium. Am J Health Sys Pharm 2007; 64:2027-2031
17. Oyesanmi O, Kunkel EJ, Monti DA, Field HL: Hematologic side effects of psychotropics. Psychosomatics 1999; 40:414-421
18. Stubner S, Grohmann R, Engel R, Bandelow B, Ludwig WD, Wagner G, Muller-Oerlinghausen B, Moller HJ, Hippius H, Ruther E: Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004; 37(suppl 1):S70-S78
19. Wong J, Delva N: Clozapine-induced seizures: recognition and treatment. Can J Psychiatry - Revue Canadienne de Psychiatrie 2007; 52:457-463
20. Haller E, Binder RL: Clozapine and seizures. Am J Psychiatry 1990; 147:1069-1071
21. Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG: Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994; 14:119-125
22. Thompson A, Girishchandra B, Castle D, Orr K: Late onset neutropenia with clozapine. Can J Psychiatry - Revue Canadienne de Psychiatrie 2004; 49:647-648
23. Pantelis C, Adesanya A: Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine. Aust N Z J Psychiatry 2001; 35:544-545
24. Devinsky O, Honigfeld G, Patin J: Clozapine-related seizures. Neurology 1991; 41:369-371
25. Shigeta M, Homma A: Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Rev 2001; 7:353-368
26. Linnet K, Olesen OV: Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 1997; 25:1379-1382
27. Tyson SC, Devane CL, Risch SC: Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 1995; 152:1401-1402
28. Godleski LS, Sernyak MJ: Agranulocytosis after addition of risperidone to clozapine treatment. Am J Psychiatry 1996; 153:735-736
29. Esposito D, Rouillon F, Limosin F: Continuing clozapine treatment despite neutropenia. Eur J Clin Pharmacol 2005; 60:759-764
30. Kanaan RA, Kerwin RW: Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatry 2006; 67:756-760
31. Paton C, Esop R: Managing clozapine-induced neutropenia with lithium. Psychiatr Bull 2005; 29:186-188
32. Gallicchio VS, Chen MG: Influence of lithium on proliferation of hematopoietic stem cells. Exp Hematol 1981; 9:804-810
33. Richman CM, Kinnealey A, Hoffman PC: Granulopoietic effects of lithium on human bone marrow in vitro. Exp Hematol 1981; 9:449-455
34. Small JG, Klapper MH, Malloy FW, Steadman TM: Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2003; 23:223-228
35. Tisman G, Herbert V, Rosenblatt S: Evidence that lithium induces human granulocyte proliferation: elevated serum vitamin B12 binding capacity in vivo and granulocyte colony proliferation in vitro. Br J Haematology 1973; 24:767-771
36. Blake LM, Marks RC, Luchins DJ: Reversible neurologic symptoms with clozapine and lithium. J Clin Psychopharmacol 1992; 12:297-299
37. Garcia G, Crismon ML, Dorson PG: Seizures in two patients after the addition of lithium to a clozapine regimen. J Clin Psychopharmacol 1994; 14:426-428
38. Blier P, Slater S, Measham T, Koch M, Wiviott G: Lithium and clozapine-induced neutropenia/agranulocytosis. Int Clin Psychopharmacology 1998; 13:137-140
39. Gerson SL, Lieberman JA, Friedenberg WR, Lee D, Marx JJ Jr, Meltzer H: Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet 1991; 338:262-263
40. Bender S, Linka T, Wolstein J, Gehendges S, Paulus HJ, Schall U, Gastpar M: Safety and efficacy of combined clozapine-lithium pharmacotherapy. Int J Neuropsychopharmacol 2004; 7:59-63
41. Heuser M, Ganser A: Colony-stimulating factors in the management of neutropenia and its complications. Ann Hematol 2005; 84:697-708
42. Bhana N: Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review. Curr Opin Oncol 2007; 19:328-335
43. Oren R, Granat E, Shtrussberg S, Matzner Y: Clozapine-induced agranulocytosis treated with granulocyte macrophage colony stimulating factor. Br J Psychiatry 1993; 162:686-687
44. Conus P, Nanzer N, Baumann P: An alternative to interruption of treatment in recurrent clozapine-induced severe neutropenia. Br J Psychiatry 2001; 179:180
45. Rajagopal G, Graham JG, Haut FF: Prevention of clozapine-induced granulocytopenia/agranulocytosis with granulocyte-colony stimulating factor (G-CSF) in an intellectually disabled patient with schizophrenia. J Intellect Disabil Res 2007; 51(part 1):82-85
46. Sperner-Unterweger B, Czeipek I, Gaggl S, Geissler D, Spiel G, Fleischhacker WW: Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (GCSF): remission despite continuous treatment with clozapine. Br J Psychiatry 1998; 172:82-84
47. Hagg S, Rosenius S, Spigset O: Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. Int Clin Psychopharmacol 2003; 18:173-174
48. Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL: Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007; 40:185-192